Clinical landscape of gene therapy for rare diseases: a registry-based analysis of clinical trials and FDA-approved products.
文献摘要
Rare diseases collectively impose a substantial health burden, yet most lack disease-modifying treatments. We conducted a registry-based cross-sectional analysis of gene therapy development for rare diseases using U.S. Food and Drug Administration (FDA) product records, Orphanet classifications, and clinical trial records retrieved through Gene Therapy Net, whose core data are derived from ClinicalTrials.gov, with an October 2025 cutoff. Of 1464 registered studies, 646 (44.13%) addressed 175 distinct rare diseases. Annual initiation of rare disease studies increased from 21 in 2015 to 73 in 2024. Hemophilia A and B, retinitis pigmentosa, Duchenne muscular dystrophy, and sickle cell disease were the most frequently studied indications. Within the rare disease cohort, 547 studies (84.67%) were interventional, 408 (63.16%) were classified as early phase I, phase I, or phase I/II, and 402 (62.23%) permitted pediatric enrollment. The United States was listed as a study location in 410 studies (63.47%). Of 30 approved gene therapy products identified, 24 (80.00%) had at least one rare disease indication, collectively covering 16 indications. Rare diseases constituted a substantial component of gene therapy development, with an expanding clinical research portfolio and established regulatory approvals. The predominance of early-phase studies and geographic concentration highlight priorities for later-phase evaluation and broader international participation.